Author

J. Pouwels

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

J. Westermarck· 2 shared U. Butt· 2 shared A. Goga· 1 shared A. N. Cvrljevic· 1 shared A. Peura· 1 shared A. Ristimaki· 1 shared B. Boeckx· 1 shared C. Bockelman· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Westermarck

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Respiratory Complex I Regulates Dendritic Cell Maturation in Explant Model of Human Tumor Immune Microenvironment

R. Turpin, R. Liu, P. Munne, A. Peura, J. H. Rannikko, G. Philips, B. Boeckx, N. Salmelin, E. Hurskainen, I. Suleymanova, E. M. Vuorinen, L. Lehtinen, M. Mutka, P. E. Kovanen, L. Niinikoski, , J. Klefstrom

The paper uses a patient-derived explant model to show metformin enhances dendritic cell maturation by inhibiting complex I, improving anti-tumor immunity when combined with venetoclax.

bioRxiv · May 10, 2023Cancer Biology

SHARPIN serine 146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion, and metastasis

U. Butt, M. H. Khan, J. Pouwels, J. Westermarck

This study identifies SHARPIN serine 146 phosphorylation as a key regulator of cancer cell invasion and metastasis by mediating ARP2/3 complex interaction and lamellopodia formation.

bioRxiv · Jan 21, 2022Cancer Biology

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

A. N. Cvrljevic, U. Butt, K. Huhtinen, T. Gronroos, C. Bockelman, H. Lassus, K. Kaipio, A. Ristimaki, T. Arsiola, T. D. Laajala, D. Connolly, O. Carpen, J. Pouwels, J. Westermarck

The paper identifies ovarian cancers with low CIP2A expression as a subtype sensitive to APR-246, a ROS-inducing compound, and shows CIP2A's role in modulating NF-kB activity and drug response.

bioRxiv · Mar 31, 2021Cancer Biology